Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Katz

Showing results (631-640 of 749) with videos related to

Pageof 75
Sort By:
Nature Communications|June 25, 2022
Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolutionMaria E Monberg, Heather Geiger, Jaewon J Lee, et al.
Annals of Surgical Oncology|January 3, 2024
Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium StudyDeesje Doppenberg, Thomas F Stoop, Susan van Dieren, et al.
The British Journal of Surgery|February 19, 2025
Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort studyEsther N Dekker, David van Klaveren, Eva M M Verkolf, et al.
Annals of Surgery|June 30, 2023
Prophylactic Antibiotic Duration and Infectious Complications in Pancreatoduodenectomy Patients With Biliary Stents: Opportunity for De-escalationArtem Boyev, Elsa M Arvide, Timothy E Newhook, et al.
Annals of Surgery|July 6, 2019
Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic CancerGiampaolo Perri, Laura Prakash, Huamin Wang, et al.
Cytokine|March 12, 2002
Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapyManuela G Neuman, Jean-Pierre Benhamou, Marc Bourliere, et al.
Clinical Biochemistry|June 16, 2001
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis CM G Neuman, J P Benhamou, I M Malkiewicz, et al.
Annals of Surgical Oncology|February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial designMatthew H G Katz, Robert Marsh, Joseph M Herman, et al.
Surgical Oncology|September 6, 2020
Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approachChing-Wei D Tzeng, Hop S Tran Cao, Christina L Roland, et al.
Annals of Surgical Oncology|January 20, 2012
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapyChing-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, et al.
Pageof 75

Showing results (631-640 of 749) with videos related to

Sort By:
Pageof 75
Nature Communications|June 25, 2022
Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolutionMaria E Monberg, Heather Geiger, Jaewon J Lee, et al.
Annals of Surgical Oncology|January 3, 2024
Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium StudyDeesje Doppenberg, Thomas F Stoop, Susan van Dieren, et al.
The British Journal of Surgery|February 19, 2025
Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort studyEsther N Dekker, David van Klaveren, Eva M M Verkolf, et al.
Annals of Surgery|June 30, 2023
Prophylactic Antibiotic Duration and Infectious Complications in Pancreatoduodenectomy Patients With Biliary Stents: Opportunity for De-escalationArtem Boyev, Elsa M Arvide, Timothy E Newhook, et al.
Annals of Surgery|July 6, 2019
Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic CancerGiampaolo Perri, Laura Prakash, Huamin Wang, et al.
Cytokine|March 12, 2002
Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapyManuela G Neuman, Jean-Pierre Benhamou, Marc Bourliere, et al.
Clinical Biochemistry|June 16, 2001
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis CM G Neuman, J P Benhamou, I M Malkiewicz, et al.
Annals of Surgical Oncology|February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial designMatthew H G Katz, Robert Marsh, Joseph M Herman, et al.
Surgical Oncology|September 6, 2020
Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approachChing-Wei D Tzeng, Hop S Tran Cao, Christina L Roland, et al.
Annals of Surgical Oncology|January 20, 2012
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapyChing-Wei D Tzeng, Jason B Fleming, Jeffrey E Lee, et al.
Pageof 75